Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/61731
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Human papillomavirus vaccine safety in Australia: experience to date and issues for surveillance |
Author: | Gold, M. Buttery, J. McIntyre, P. |
Citation: | Sexual Health, 2010; 7(3):320-324 |
Publisher: | Csiro Publishing |
Issue Date: | 2010 |
ISSN: | 1448-5028 1449-8987 |
Statement of Responsibility: | Michael S. Gold, Jim Buttery and Peter McIntyre |
Abstract: | Australia was one of the first countries to licence a quadrivalent human papillomavirus (HPV) vaccine, rapidly followed by a federally funded program of universal vaccination of a broad age group of females through schools (12 to 18 years) and primary care (19 to 26 years). As of August 2009, more than 5.8 million doses of Gardasil® (quadrivalent; Merck, New Jersey, USA) have been distributed in Australia and a total of 1394 suspected adverse events following immunisation (AEFI) have been reported to the passive surveillance system. Most reports are of common and expected reactions. Case series of more uncommon and serious AEFI, both known to be potentially vaccine related (anaphylaxis, conversion disorders and lipoatrophy) and otherwise (multiple sclerosis and pancreatitis) have been published. |
Keywords: | adverse events following immunisations HPV vaccine vaccine safety |
Rights: | Copyright CSIRO 2010 |
DOI: | 10.1071/SH09153 |
Published version: | http://dx.doi.org/10.1071/sh09153 |
Appears in Collections: | Aurora harvest 5 Paediatrics publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.